Top

Published in:

01-10-2020 | Review

Role of Silent Information Regulator 1 (SIRT1) in Regulating Oxidative Stress and Inflammation

Authors: Vivek Singh, Saba Ubaid

Published in: Inflammation | Issue 5/2020

Abstract

Silent information regulator 1 (SIRT1) is a ubiquitously expressed protein and has an intricate role in the pathology, progression, and treatment of several diseases. SIRT1 is a NAD+-dependent deacetylase and regulates gene expression by histone deacetylation. Deletion of SIRT1 in the liver, pancreas, and brain significantly increases the reactive oxygen species (ROS) and inflammatory response. Literature survey on SIRT1 shows the evidence for its role in preventing oxidative stress and inflammation. Oxidative stress and inflammation are closely related pathophysiological processes and are involved in the pathogenesis of a number of chronic disorders such as fatty liver diseases, diabetes, and neurodegenerative diseases. Both oxidative stress and inflammation alter the expression of several genes such as nuclear factor E2 related factor (Nrf2), nuclear factor E2 related factor 2 (Nef2), nuclear factor kappa B (NF-kB), pancreatic and duodenal homeobox factor 1 (PDX1), interleukin-1 (IL1), forkhead box class O (FOXO), and tumour necrosis factor alpha (TNF-α). By annotating this knowledge, we can conclude that modulating the expression of SIRT1 might prevent the onset of diseases inexorably linked to the liver, pancreas, and brain.

Gregoretti, I., Y.M. Lee, and H.V. Goodson. 2004 Apr 16. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. Journal of Molecular Biology 338 (1): 17–31.PubMed

Finkel, T., C.X. Deng, and R. Mostoslavsky. 2009 Jul. Recent progress in the biology and physiology of sirtuins. Nature. 460 (7255): 587–591.PubMedPubMedCentral

Deng, G.F., X.R. Xu, Y. Zhang, D. Li, R.Y. Gan, and H.B. Li. 2013 Jan 1. Phenolic compounds and bioactivities of pigmented rice. Critical Reviews in Food Science and Nutrition 53 (3): 296–306.PubMed

Price, N.L., A.P. Gomes, A.J. Ling, F.V. Duarte, A. Martin-Montalvo, B.J. North, B. Agarwal, L. Ye, G. Ramadori, J.S. Teodoro, and B.P. Hubbard. 2012 May 2. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metabolism 15 (5): 675–690.PubMedPubMedCentral

Tanno, M., J. Sakamoto, T. Miura, K. Shimamoto, and Y. Horio. 2007 Mar 2. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. The Journal of Biological Chemistry 282 (9): 6823–6832.PubMed

Kang, H., J.Y. Suh, Y.S. Jung, J.W. Jung, M.K. Kim, and J.H. Chung. 2011 Oct 21. Peptide switch is essential for Sirt1 deacetylase activity. Molecular Cell 44 (2): 203–213.PubMedPubMedCentral

Davenport, A.M., F.M. Huber, and A. Hoelz. 2014 Feb 6. Structural and functional analysis of human SIRT1. Journal of Molecular Biology 426 (3): 526–541.PubMed

Han, C., Y. Gu, H. Shan, W. Mi, J. Sun, M. Shi, X. Zhang, X. Lu, F. Han, Q. Gong, and W. Yu. 2017 Nov 14. O-GlcNAcylation of SIRT1 enhances its deacetylase activity and promotes cytoprotection under stress. Nature Communications 8 (1): 1–2.

Caldwell, S.H., D.H. Oelsner, J.C. Iezzoni, E.E. Hespenheide, E.H. Battle, and C.J. Driscoll. 1999 Mar. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology. 29 (3): 664–669.PubMed

10.

Shimada, M., E. Hashimoto, M. Taniai, K. Hasegawa, H. Okuda, N. Hayashi, K. Takasaki, and J. Ludwig. 2002 Jul 1. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Journal of Hepatology 37 (1): 154–160.PubMed

11.

Propst, A., T. Propst, G. Judmaier, and W. Vogel. 1995 May 1. Prognosis in nonalcoholic steatohepatitis. Gastroenterology. 108 (5): 1607.PubMed

12.

Sheth, S.G., F.D. Gordon, and S. Chopra. 1997 Jan 15. Nonalcoholic steatohepatitis. Annals of Internal Medicine 126 (2): 137–145.PubMed

13.

Ludwig J, Viggiano TR, Mcgill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. In Mayo Clinic Proceedings 1980 Jul (Vol. 55, No. 7, pp. 434–438).

14.

Ding, R.B., K. Tian, C.W. He, Y. Jiang, Y.T. Wang, and J.B. Wan. 2012 Dec 18. Herbal medicines for the prevention of alcoholic liver disease: A review. Journal of Ethnopharmacology 144 (3): 457–465.PubMed

15.

Feldstein AE, Bailey SM. Emerging role of redox dysregulation in alcoholic and nonalcoholic fatty liver disease.

16.

Liu, W., R.D. Baker, T. Bhatia, L. Zhu, and S.S. Baker. 2016 May 1. Pathogenesis of nonalcoholic steatohepatitis. Cellular and Molecular Life Sciences 73 (10): 1969–1987.PubMed

17.

Caligiuri, A., A. Gentilini, and F. Marra. 2016 Sep. Molecular pathogenesis of NASH. International Journal of Molecular Sciences 17 (9): 1575.PubMedCentral

18.

Tak, P.P., and G.S. Firestein. 2001 Jan 1. NF-κB: A key role in inflammatory diseases. The Journal of Clinical Investigation 107 (1): 7–11.PubMedPubMedCentral

19.

Mulero, M.C., D.B. Huang, H.T. Nguyen, V.Y. Wang, Y. Li, T. Biswas, and G. Ghosh. 2017 Nov 17. DNA-binding affinity and transcriptional activity of the RelA homodimer of nuclear factor κB are not correlated. The Journal of Biological Chemistry 292 (46): 18821–18830.PubMedPubMedCentral

20.

Yeung, F., J.E. Hoberg, C.S. Ramsey, M.D. Keller, D.R. Jones, R.A. Frye, and M.W. Mayo. 2004 Jun 16. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. The EMBO Journal 23 (12): 2369–2380.PubMedPubMedCentral

21.

Shen, Z., J.M. Ajmo, C.Q. Rogers, X. Liang, L. Le, M.M. Murr, Y. Peng, and M. You. 2009 May. Role of SIRT1 in regulation of LPS-or two ethanol metabolites-induced TNF-α production in cultured macrophage cell lines. American Journal of Physiology. Gastrointestinal and Liver Physiology 296 (5): G1047–G1053.PubMedPubMedCentral

22.

Xu, F., Z. Gao, J. Zhang, C.A. Rivera, J. Yin, J. Weng, and J. Ye. 2010 Jun 1. Lack of SIRT1 (mammalian sirtuin 1) activity leads to liver steatosis in the SIRT1+/− mice: A role of lipid mobilization and inflammation. Endocrinology. 151 (6): 2504–2514.PubMedPubMedCentral

23.

Schug, T.T., Q. Xu, H. Gao, A. Peres-da-Silva, D.W. Draper, M.B. Fessler, A. Purushotham, and X. Li. 2010 Oct 1. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Molecular and Cellular Biology 30 (19): 4712–4721.PubMedPubMedCentral

24.

Pfluger, P.T., D. Herranz, S. Velasco-Miguel, M. Serrano, and M.H. Tschöp. 2008 Jul 15. Sirt1 protects against high-fat diet-induced metabolic damage. Proceedings of the National Academy of Sciences 105 (28): 9793–9798.

25.

Tang, W., Y.F. Jiang, M. Ponnusamy, and M. Diallo. 2014 Sep 28. Role of Nrf2 in chronic liver disease. World journal of gastroenterology: WJG 20 (36): 13079–13087.PubMedPubMedCentral

26.

Kansanen, E., A.M. Kivelä, and A.L. Levonen. 2009 Nov 1. Regulation of Nrf2-dependent gene expression by 15-deoxy-Δ12, 14-prostaglandin J2. Free Radical Biology & Medicine 47 (9): 1310–1317.

27.

Zhang, Y.K., K.C. Wu, and C.D. Klaassen. 2013. Genetic activation of Nrf2 protects against fasting-induced oxidative stress in livers of mice. PLoS One 8 (3): e59122.

28.

Yin, H., M. Hu, X. Liang, J.M. Ajmo, X. Li, R. Bataller, G. Odena, S.M. Stevens Jr., and M. You. 2014 Mar 1. Deletion of SIRT1 from hepatocytes in mice disrupts lipin-1 signaling and aggravates alcoholic fatty liver. Gastroenterology. 146 (3): 801–811.PubMed

29.

Wang, R.H., C. Li, and C.X. Deng. 2010. Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition. International Journal of Biological Sciences 6 (7): 682–690.PubMedPubMedCentral

30.

Wright, E., Jr., J.L. Scism-Bacon, and L.C. Glass. 2006 Mar. Oxidative stress in type 2 diabetes: The role of fasting and postprandial glycaemia. International Journal of Clinical Practice 60 (3): 308–314.PubMedPubMedCentral

31.

Kawamori, D., Y. Kajimoto, H. Kaneto, Y. Umayahara, Y. Fujitani, T. Miyatsuka, H. Watada, I.B. Leibiger, Y. Yamasaki, and M. Hori. 2003 Dec 1. Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun NH2-terminal kinase. Diabetes. 52 (12): 2896–2904.PubMed

32.

Jonsson, J., L. Carlsson, T. Edlund, and H. Edlund. 1994 Oct 13. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature. 371 (6498): 606–609.PubMed

33.

Sharma, A., D.H. Zangen, P. Reitz, M. Taneja, M.E. Lissauer, C.P. Miller, G.C. Weir, J.F. Habener, and S. Bonner-Weir. 1999 Mar 1. The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration. Diabetes. 48 (3): 507–513.PubMed

34.

Ahlgren, U., J. Jonsson, L. Jonsson, K. Simu, and H. Edlund. 1998 Jun 15. β-Cell-specific inactivation of the mouseIpf1/Pdx1 gene results in loss of the β-cell phenotype and maturity onset diabetes. Genes & Development 12 (12): 1763–1768.

35.

Staffers, D.A., J. Ferrer, W.L. Clarke, and J.F. Habener. 1997 Oct. Early-onset type-ll diabetes mellitus (MODY4) linked to IPF1. Nature Genetics 17 (2): 138–139.

36.

Wang, R.H., X. Xu, H.S. Kim, Z. Xiao, and C.X. Deng. 2013. SIRT1 deacetylates FOXA2 and is critical for Pdx1 transcription and β-cell formation. International Journal of Biological Sciences 9 (9): 934–946.PubMedPubMedCentral

37.

Wu, L., L. Zhou, Y. Lu, J. Zhang, F. Jian, Y. Liu, F. Li, W. Li, X. Wang, and G. Li. 2012 Nov 1. Activation of SIRT1 protects pancreatic β-cells against palmitate-induced dysfunction. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1822 (11): 1815–1825.

38.

Kaneto, H., G. Xu, N. Fujii, S. Kim, S. Bonner-Weir, and G.C. Weir. 2002 Aug 16. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. The Journal of Biological Chemistry 277 (33): 30010–30018.PubMed

39.

Jia, Y., Z. Zheng, Y. Wang, Q. Zhou, W. Cai, W. Jia, L. Yang, M. Dong, X. Zhu, L. Su, and D. Hu. 2015. SIRT1 is a regulator in high glucose-induced inflammatory response in RAW264. 7 cells. PLoS One 10 (3): e0120849.

40.

Elmarakby, A.A., and J.C. Sullivan. 2012 Feb. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovascular Therapeutics 30 (1): 49–59.PubMed

41.

Spranger, J., A. Kroke, M. Möhlig, K. Hoffmann, M.M. Bergmann, M. Ristow, H. Boeing, and A.F. Pfeiffer. 2003 Mar 1. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 52 (3): 812–817.PubMed

42.

Herder, C., T. Illig, W. Rathmann, S. Martin, B. Haastert, S. Müller-Scholze, R. Holle, B. Thorand, W. Koenig, H.E. Wichmann, and H. Kolb. 2005 Aug. Inflammation and type 2 diabetes: Results from KORA Augsburg. Das Gesundheitswesen 67 (S 01): 115–121.

43.

Herder, C., E.J. Brunner, W. Rathmann, K. Strassburger, A.G. Tabak, N.C. Schloot, and D.R. Witte. 2009. Elevated levels of the anti- inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: The Whitehall II study. Diabetes Care 32: 421–423.PubMedPubMedCentral

44.

Pradhan, A.D., J.E. Manson, N. Rifai, J.E. Buring, and P.M. Ridker. 2001 Jul 18. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama. 286 (3): 327–334.PubMed

45.

Ehses, J.A., A. Perren, E. Eppler, P. Ribaux, J.A. Pospisilik, R. Maor-Cahn, X. Gueripel, H. Ellingsgaard, M.K. Schneider, G. Biollaz, and A. Fontana. 2007 Sep 1. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 56 (9): 2356–2370.PubMed

46.

Westwell-Roper, C.Y., J.A. Ehses, and C.B. Verchere. 2014 May 1. Resident macrophages mediate islet amyloid polypeptide–induced islet IL-1β production and β-cell dysfunction. Diabetes. 63 (5): 1698–1711.PubMed

47.

Yoshizaki, T., J.C. Milne, T. Imamura, S. Schenk, N. Sonoda, J.L. Babendure, J.C. Lu, J.J. Smith, M.R. Jirousek, and J.M. Olefsky. 2009 Mar 1. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Molecular and Cellular Biology 29 (5): 1363–1374.PubMed

48.

Yoshizaki, T., S. Schenk, T. Imamura, J.L. Babendure, N. Sonoda, E.J. Bae, D.Y. Oh, M. Lu, J.C. Milne, C. Westphal, and G. Bandyopadhyay. 2010 Mar. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. American Journal of Physiology. Endocrinology and Metabolism 298 (3): E419–E428.PubMed

49.

Pelvig, D.P., H. Pakkenberg, A.K. Stark, and B. Pakkenberg. 2008 Nov 1. Neocortical glial cell numbers in human brains. Neurobiology of Aging 29 (11): 1754–1762.PubMed

50.

Konitsiotis, S., S. Bostantjopoulou, M. Chondrogiorgi, Z. Katsarou, G. Tagaris, I. Mavromatis, E.E. Ntzani, G. Mentenopoulos, and Greek Parkinson Study Group. 2014 Aug 15. Clinical characteristics of Parkinson’s disease patients in Greece: A multicenter, nation-wide, cross-sectional study. Journal of the Neurological Sciences 343 (1–2): 36–40.PubMed

51.

Thomas, B., and M.F. Beal. 2011. Molecular insights into Parkinson’s disease. F1000 Medicine Reports 3: 7.

52.

Aarsland, D., J. Zaccai, and C. Brayne. 2005. A systematic review of prevalence studies of dementia in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 20 (10): 1255–1263.

53.

Reijnders, J.S., U. Ehrt, W.E. Weber, D. Aarsland, and A.F. Leentjens. 2008 Jan 30. A systematic review of prevalence studies of depression in Parkinson’s disease. Movement Disorders 23 (2): 183–189.PubMed

54.

Gautier, C.A., O. Corti, and A. Brice. 2014 May 1. Mitochondrial dysfunctions in Parkinson’s disease. Revista de Neurologia 170 (5): 339–343.

55.

Renault, V.M., P.U. Thekkat, K.L. Hoang, J.L. White, C.A. Brady, D.K. Broz, O.S. Venturelli, T.M. Johnson, P.R. Oskoui, Z. Xuan, and E.E. Santo. 2011 Jul. The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor. Oncogene. 30 (29): 3207–3221.PubMedPubMedCentral

56.

Langley, E., M. Pearson, M. Faretta, U.M. Bauer, R.A. Frye, S. Minucci, P.G. Pelicci, and T. Kouzarides. 2002 May 15. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. The EMBO Journal 21 (10): 2383–2396.PubMedPubMedCentral

57.

Brunet, A., A. Bonni, M.J. Zigmond, M.Z. Lin, P. Juo, L.S. Hu, M.J. Anderson, K.C. Arden, J. Blenis, M.E. Greenberg, et al. 1999 Mar 19. cell 96 (6): 857–868.PubMed

58.

Cho, S.H., J.A. Chen, F. Sayed, M.E. Ward, F. Gao, T.A. Nguyen, G. Krabbe, P.D. Sohn, I. Lo, S. Minami, and N. Devidze. 2015 Jan 14. SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β. The Journal of Neuroscience 35 (2): 807–818.PubMedPubMedCentral

59.

Saijo, K., B. Winner, C.T. Carson, J.G. Collier, L. Boyer, M.G. Rosenfeld, F.H. Gage, and C.K. Glass. 2009 Apr 3. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 137 (1): 47–59.PubMedPubMedCentral

60.

Leal, M.C., J.C. Casabona, M. Puntel, and F. PITOSSI. 2013 Apr 29. Interleukin-1β and tumor necrosis factor-α: Reliable targets for protective therapies in Parkinson’s disease? Frontiers in Cellular Neuroscience 7: 53.PubMedPubMedCentral

61.

Benner, E.J., R. Banerjee, A.D. Reynolds, S. Sherman, V.M. Pisarev, V. Tsiperson, C. Nemachek, P. Ciborowski, S. Przedborski, R.L. Mosley, and H.E. Gendelman. 2008. Nitrated α–synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 3 (1): e1376.

62.

Tansey, M.G., M.K. McCoy, and T.C. Frank-Cannon. 2007 Nov 1. Neuroinflammatory mechanisms in Parkinson’s disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Experimental Neurology 208 (1): 1–25.PubMedPubMedCentral

63.

Ferrari, C.C., M.C. Godoy, R. Tarelli, M. Chertoff, A.M. Depino, and F.J. Pitossi. 2006 Oct 1. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra. Neurobiology of Disease 24 (1): 183–193.PubMed

64.

Ye, J., Z. Liu, J. Wei, L. Lu, Y. Huang, L. Luo, and H. Xie. 2013 Oct 11. Protective effect of SIRT1 on toxicity of microglial-derived factors induced by LPS to PC12 cells via the p53-caspase-3-dependent apoptotic pathway. Neuroscience Letters 553: 72–77.PubMed

65.

Tennen, R.I., E. Michishita-Kioi, and K.F. Chua. 2012 Feb 3. Finding a target for resveratrol. Cell. 148 (3): 387–389.PubMed

66.

Cao, D., M. Wang, X. Qiu, D. Liu, H. Jiang, N. Yang, and R.M. Xu. 2015 Jun 15. Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol. Genes & Development 29 (12): 1316–1325.

67.

Hubbard, B.P., A.P. Gomes, H. Dai, J. Li, A.W. Case, T. Considine, T.V. Riera, J.E. Lee, D.W. Lamming, B.L. Pentelute, and E.R. Schuman. 2013 Mar 8. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science. 339 (6124): 1216–1219.PubMedPubMedCentral

68.

Hou, X., D. Rooklin, H. Fang, and Y. Zhang. 2016 Nov 30. Resveratrol serves as a protein-substrate interaction stabilizer in human SIRT1 activation. Scientific Reports 6: 38186.PubMedPubMedCentral

69.

Modi, S., N. Yaluri, T. Kokkola, and M. Laakso. 2017 Dec 14. Plant-derived compounds strigolactone GR24 and pinosylvin activate SIRT1 and enhance glucose uptake in rat skeletal muscle cells. Scientific Reports 7 (1): 1–1.

70.

Zeng, W., W. Shan, L. Gao, D. Gao, Y. Hu, G. Wang, N. Zhang, Z. Li, X. Tian, W. Xu, and J. Peng. 2015 Nov 3. Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease. Scientific Reports 5: 16013.PubMedPubMedCentral

71.

Bai, X., L. Yao, X. Ma, and X. Xu. 2018 Aug 1. Small molecules as SIRT modulators. Mini Reviews in Medicinal Chemistry 18 (13): 1151–1157.PubMed

72.

Qiu, L., Y. Luo, and X. Chen. 2018 Jul 1. Quercetin attenuates mitochondrial dysfunction and biogenesis via upregulated AMPK/SIRT1 signaling pathway in OA rats. Biomedicine & Pharmacotherapy 103: 1585–1591.

73.

Hung, C.H., S.H. Chan, P.M. Chu, and K.L. Tsai. 2015 Oct. Quercetin is a potent anti-atherosclerotic compound by activation of SIRT1 signaling under oxLDL stimulation. Molecular Nutrition & Food Research 59 (10): 1905–1917.

74.

Kim, S.C., Y.H. Kim, S.W. Son, E.Y. Moon, S. Pyo, and S.H. Um. 2015 Nov 27. Fisetin induces Sirt1 expression while inhibiting early adipogenesis in 3T3-L1 cells. Biochemical and Biophysical Research Communications 467 (4): 638–644.PubMed

75.

Zhang, C., C. Li, S. Chen, Z. Li, L. Ma, X. Jia, K. Wang, J. Bao, Y. Liang, M. Chen, and P. Li. 2017 Jan 23. Hormetic effect of panaxatriol saponins confers neuroprotection in PC12 cells and zebrafish through PI3K/AKT/mTOR and AMPK/SIRT1/FOXO3 pathways. Scientific Reports 7 (1): 1–2.

76.

Wang, Y., X. Liang, Y. Chen, and X. Zhao. 2016. Screening SIRT1 activators from medicinal plants as bioactive compounds against oxidative damage in mitochondrial function. Oxidative Medicine and Cellular Longevity 2016: 1–9.

77.

Villalba, J.M., and F.J. Alcaín. 2012 Sep. Sirtuin activators and inhibitors. Biofactors. 38 (5): 349–359.PubMedPubMedCentral

78.

Alcaín, F.J., and J.M. Villalba. 2009 Apr 1. Sirtuin activators. Expert Opinion on Therapeutic Patents 19 (4): 403–414.PubMed

79.

Ishisaka, A., S. Ichikawa, H. Sakakibara, M.K. Piskula, T. Nakamura, Y. Kato, M. Ito, K.I. Miyamoto, A. Tsuji, Y. Kawai, and J. Terao. 2011 Oct 1. Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats. Free Radical Biology & Medicine 51 (7): 1329–1336.

80.

Youdim, K.A., M.Z. Qaiser, D.J. Begley, C.A. Rice-Evans, and N.J. Abbott. 2004 Mar 1. Flavonoid permeability across an in situ model of the blood–brain barrier. Free Radical Biology & Medicine 36 (5): 592–604.

81.

Zhou, Y., S. Wang, Y. Li, S. Yu, and Y. Zhao. 2018 Jan 9. SIRT1/PGC-1α signaling promotes mitochondrial functional recovery and reduces apoptosis after intracerebral hemorrhage in rats. Frontiers in Molecular Neuroscience 10: 443.PubMedPubMedCentral

82.

Bhullar, K.S., and B.P. Hubbard. 2015 Jun 1. Lifespan and healthspan extension by resveratrol. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1852 (6): 1209–1218.

83.

Zhang, N., Y. Hu, C. Ding, W. Zeng, W. Shan, H. Fan, Y. Zhao, X. Shi, L. Gao, T. Xu, and R. Wang. 2017 Feb 5. Salvianolic acid B protects against chronic alcoholic liver injury via SIRT1-mediated inhibition of CRP and ChREBP in rats. Toxicology Letters 267: 1–10.PubMed

84.

Yang, Q.Y., X.D. Lai, J. Ouyang, and J.D. Yang. 2018 Nov 1. Effects of Ginsenoside Rg3 on fatigue resistance and SIRT1 in aged rats. Toxicology. 409: 144–151.PubMed

85.

Huang, Y., K.K. Kwan, K.W. Leung, P. Yao, H. Wang, T.T. Dong, and K.W. Tsim. 2019 Oct 1. Ginseng extracts modulate mitochondrial bioenergetics of live cardiomyoblasts: A functional comparison of different extraction solvents. Journal of Ginseng Research 43 (4): 517–526.PubMed

86.

Kim, D.H., C.H. Park, D. Park, Y.J. Choi, M.H. Park, K.W. Chung, S.R. Kim, J.S. Lee, and H.Y. Chung. 2014 Jun 1. Ginsenoside Rc modulates Akt/FoxO1 pathways and suppresses oxidative stress. Archives of Pharmacal Research 37 (6): 813–820.PubMed

87.

Minor, R.K., J.A. Baur, A.P. Gomes, T.M. Ward, A. Csiszar, E.M. Mercken, K. Abdelmohsen, Y.K. Shin, C. Canto, M. Scheibye-Knudsen, and M. Krawczyk. 2011 Aug 18. SRT1720 improves survival and healthspan of obese mice. Scientific Reports 1: 70.PubMedPubMedCentral

88.

Milne, J.C., P.D. Lambert, S. Schenk, D.P. Carney, J.J. Smith, D.J. Gagne, L. Jin, O. Boss, R.B. Perni, C.B. Vu, and J.E. Bemis. 2007 Nov. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 450 (7170): 712–716.PubMedPubMedCentral

89.

Gurt, I., H. Artsi, E. Cohen-Kfir, G. Hamdani, G. Ben-Shalom, B. Feinstein, M. El-Haj, and R. Dresner-Pollak. 2015. The Sirt1 activators SRT2183 and SRT3025 inhibit RANKL-induced osteoclastogenesis in bone marrow-derived macrophages and down-regulate Sirt3 in Sirt1 null cells. PLoS One 10 (7): e0134391.

90.

Campagna, J., P. Spilman, B. Jagodzinska, D. Bai, A. Hatami, C. Zhu, T. Bilousova, M. Jun, C.J. Elias, J. Pham, and G. Cole. 2018 Dec 4. A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer’s disease mouse model. Scientific Reports 8 (1): 1–5.

91.

Ögren, S.O., A.C. Holm, H. Hall, and U.H. Lindberg. 1984 Dec 1. Alaproclate, a new selective 5-HT uptake inhibitor with therapeutic potential in depression and senile dementia. Journal of Neural Transmission 59 (4): 265–288.PubMed

92.

Kim, M.J., H.J. An, D.H. Kim, B. Lee, H.J. Lee, S. Ullah, S.J. Kim, H.O. Jeong, K.M. Moon, E.K. Lee, and J. Yang. 2018 Feb 15. Novel SIRT1 activator MHY2233 improves glucose tolerance and reduces hepatic lipid accumulation in db/db mice. Bioorganic & Medicinal Chemistry Letters 28 (4): 684–688.

93.

Yao, Z.Q., X. Zhang, Y. Zhen, X.Y. He, S. Zhao, X.F. Li, B. Yang, F. Gao, F.Y. Guo, L. Fu, and X.Z. Liu. 2018 Jul 10. A novel small-molecule activator of Sirtuin-1 induces autophagic cell death/mitophagy as a potential therapeutic strategy in glioblastoma. Cell Death & Disease 9 (7): 1–4.

Title: Role of Silent Information Regulator 1 (SIRT1) in Regulating Oxidative Stress and Inflammation
Authors: Vivek Singh
Saba Ubaid
Publication date: 01-10-2020
Publisher: Springer US
Published in: Inflammation / Issue 5/2020
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-020-01242-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Role of Silent Information Regulator 1 (SIRT1) in Regulating Oxidative Stress and Inflammation

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

PM2.5 Exposure Induces Inflammatory Response in Macrophages via the TLR4/COX-2/NF-κB Pathway

Knockdown of H19 Inhibits the Pathogenesis of Acne Vulgaris by Targeting the miR-196a/TLR2/NF-κB Axis

The Antioxidant Rosmarinic Acid Ameliorates Oxidative Lung Damage in Experimental Allergic Asthma via Modulation of NADPH Oxidases and Antioxidant Enzymes

Anti-inflammatory Activity of Mesenchymal Stem Cells in λ-Carrageenan-Induced Chronic Inflammation in Rats: Reactions of the Blood System, Leukocyte-Monocyte Ratio

Overexpression of Peroxisome Proliferator-Activated Receptor γ Coactivator 1-α Protects Cardiomyocytes from Lipopolysaccharide-Induced Mitochondrial Damage and Apoptosis

Protective Effects of SIRT6 Against Inflammation, Oxidative Stress, and Cell Apoptosis in Spinal Cord Injury

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page